








## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> C07D 235/18, 471/04, 403/12, 401/12, A61K 31/415, 31/435, 31/505 // (C07D 471/04, 235:00, 221:00)	<b>A1</b>	<b>(11) International Publication Number:</b> WO 95/30659  <b>(43) International Publication Date:</b> 16 November 1995 (16.11.95)
<b>(21) International Application Number:</b> PCT/US95/03816  <b>(22) International Filing Date:</b> 27 March 1995 (27.03.95)  <b>(30) Priority Data:</b> 08/240,355                      10 May 1994 (10.05.94)                      US  <b>(71) Applicant:</b> WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07590 (US).  <b>(72) Inventors:</b> DOWNING, Dennis, Michael; 1730 Dunmore, Ann Arbor, MI 48103 (US). GLASE, Shelly, Ann; 1533 Natalie Lane #203, Ann Arbor, MI 48105 (US). JOHNSON, Stephen, Joseph; 1059 Shady Oaks Drive, Ann Arbor, MI 48105 (US). WISE, Lawrence, David; 1241 Barrister, Ann Arbor, MI 48105 (US). WRIGHT, Jonathan, Leonard; 2311 Fernwood, Ann Arbor, MI 48104 (US).  <b>(74) Agents:</b> RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		<b>(81) Designated States:</b> AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ. European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMIN- ERGIC AGENTS, ESP. SELECTIVE FOR THE DOPAMINE D3 RECEPTOR  <div style="text-align: center;">  <p style="text-align: right;">(I)</p> </div> <div style="display: flex; justify-content: space-around; margin-top: 20px;"> <div style="text-align: center;">  <p>(a)</p> </div> <div style="text-align: center;">  <p>(b)</p> </div> </div> <div style="display: flex; justify-content: space-around; margin-top: 20px;"> <div style="text-align: center;">  <p>(c)</p> </div> <div style="text-align: center;">  <p>(d)</p> </div> </div>		
<b>(57) Abstract</b>  Benzimidazoles and imidazopyridines of formula (I) wherein: R is (a) wherein R <sup>1</sup> is aryl, or heteroaryl, or (b) wherein R <sup>1</sup> is as defined above; R <sup>2</sup> is hydrogen, or alkyl of from 1 to 6 carbon atoms; X is -Y-(CH <sub>2</sub> ) <sub>n</sub> - wherein Y is O, S or NH, and n is an integer from 2 to 5, (c) wherein p is an integer from 1 to 4, (d) wherein p is as defined above, alkyl of from 3 to 6 carbon atoms, alkenyl of from 3 to 6 carbon atoms, alkynyl of from 3 to 6 carbon atoms; Z is N or CH; and corresponding isomers thereof; or a pharmaceutically acceptable acid addition salt thereof, are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antipsychotic agents and for the treatment of disorders which respond to dopaminergic blockade including psychotic depression, substance abuse, and compulsive disorders.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE  
AS DOPAMINERGIC AGENTS, ESP. SELECTIVE FOR THE DOPAMINE D3 RECEPTOR

## 5 BACKGROUND OF THE INVENTION

The present invention relates to novel substituted benzimidazoles and imidazopyridines useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to pharmaceutical methods of treatment. The novel compounds of the present invention are central nervous system agents. More particularly, the novel compounds of the present invention are dopaminergic agents useful as antipsychotic agents for treating psychoses such as schizophrenia.

Dopamine D2 antagonists are established as antipsychotic agents. More recently, the dopamine D3 receptor has been identified (Schwartz Jean-Charles, et al., The Dopamine D3 Receptor as a Target for Antipsychotics. In Novel Antipsychotic Drugs, Meltzer H.Y., Ed., Raven Press, New York, 1992, p. 135-144). On the basis of the localization of the dopamine D3 receptor in the limbic area of the brain, a selective D3 antagonist should show antipsychotic activity but not have the neurological side effects of D2 antagonists (Sokoloff P., et al., Molecular Cloning and Characterization of a Novel Dopamine Receptor (D<sub>3</sub>) as a Target for Neuroleptics, Nature, 347:146 (1990); Sokoloff P., et al., Localization and Function of the D<sub>3</sub> Dopamine Receptor, Arzneim.-Forsch./Drug Res., 42(1):224, (1992)).

The compounds of the present invention are also useful for the treatment of disorders which respond to dopaminergic blockade which include psychotic


-2-

depression, substance abuse (Caine S.B. and Koob G.F.,  
Modulation of Cocaine Self-Administration in the Rat  
Through D-3 Dopamine Receptors, Science, 260:1814  
(1993)), and compulsive disorders (Goodman W.K.,  
5 et al., The role of serotonin and dopamine in the  
pathophysiology of obsessive compulsive disorder,  
International Clinical Psychopharmacology,  
7(Supp. 1):35 (1992)).



We have surprisingly and unexpectedly found that a  
10 series of benzimidazoles and imidazopyridines are  
dopaminergic agents which bind selectively to the  
dopamine D3 receptor and are thus useful as  
antipsychotic agents for treating psychoses such as  
schizophrenia.

## SUMMARY OF THE INVENTION

Accordingly, the present invention is a compound  
of Formula I



wherein R is

wherein R<sup>1</sup> is aryl, or heteroaryl, or

-3-


wherein  $R^1$  is as defined above;

$R^2$  is hydrogen, or


alkyl of from 1 to 6 carbon atoms;

X is  $-Y-(CH_2)_n-$

5 wherein Y is O, S or NH, and n is an integer from 2 to 5,



10 wherein p is an integer from 1 to 4,



15 wherein p is as defined above,  
alkyl of from 3 to 6 carbon atoms,  
alkenyl of from 3 to 6 carbon atoms,  
alkynyl of from 3 to 6 carbon atoms;

Z is N or CH;

and corresponding isomers thereof;

20 or a pharmaceutically acceptable acid addition salt thereof.

As dopaminergic agents selective for the dopamine D3 receptor subtype, the compounds of Formula I are useful as antipsychotic agents for treating psychoses  
25 such as schizophrenia. They are also useful for the treatment of disorders which respond to dopaminergic blockade. Thus, other embodiments of the present invention include the treatment, by a compound of Formula I, of psychotic depression, substance abuse,  
30 and compulsive disorders.

A still further embodiment of the present invention is a pharmaceutical composition for administering an effective amount of a compound of Formula I in unit dosage form in the treatment methods  
35 mentioned above. Finally, the present invention is directed to methods for production of a compound of Formula I.

-4-

## DETAILED DESCRIPTION OF THE INVENTION

In the compounds of Formula I, the term "alkyl" means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like.

The term "alkenyl" means a straight or branched unsaturated hydrocarbon radical having from 3 to 6 carbon atoms and includes, for example, 2-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, and the like.

The term "alkynyl" means a straight or branched triple bonded unsaturated hydrocarbon radical having from 3 to 6 carbon atoms and includes, for example, 2-propynyl, 1-butyne, 2-butyne, 3-butyne, 1-pentyne, 3-pentyne, 1-hexynyl, 2-hexynyl, 3-hexynyl, and the like.

"Alkoxy" and "thioalkoxy" are O-alkyl or S-alkyl of from 1 to 6 carbon atoms as defined above for "alkyl".

The term "aryl" means an aromatic radical which is a phenyl group, a phenyl group substituted by 1 to 4 substituents selected from alkyl as defined above, alkoxy as defined above, thioalkoxy as defined above, hydroxy, halogen, trifluoromethyl, amino, alkylamino as defined above for alkyl, dialkylamino as defined for alkyl, or 1,3-benzodioxol-5-yl.

The term "heteroaryl" means a heteroaromatic radical which is 2-, 3-, or 4-pyridinyl, 2-, 4-, or 5-pyrimidinyl, or 2-, or 3-thienyl.

"Halogen" is fluorine, chlorine, bromine, or iodine.

-5-

"Alkali metal" is a metal in Group IA of the periodic table and includes, for example, lithium, sodium, potassium, and the like.

5 The compounds of Formula I are capable of further forming pharmaceutically acceptable acid addition salts. These forms are within the scope of the present invention.

Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from  
10 nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic  
15 acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate,  
20 metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate,  
25 benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M., et al.,  
30 "Pharmaceutical Salts", Journal of Pharmaceutical Science, 66:1-19 (1977)).

The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the  
35 salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a


-6-

base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.


Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

Certain of the compounds of the present invention may exist as a mixture of cis and trans isomers or as the individual cis and trans isomers. The mixture of isomers as well as the individual isomers are intended to be encompassed within the scope of the present invention.

A preferred compound of Formula I is one



wherein R<sup>1</sup> is aryl, or heteroaryl, or




R<sup>2</sup> is hydrogen,  
methyl, or  
ethyl;

X is -Y-(CH<sub>2</sub>)<sub>n</sub>-


wherein Y is O or NH and n is an integer from 3 to 4,



-7-



5



butyl,  
butenyl, or  
butynyl;

10

Z is N or CH;

and corresponding isomers thereof; or a  
pharmaceutically acceptable acid addition salt thereof.

Particularly valuable are:

15 2-[4-[3-(4-Phenyl-1-piperazinyl)propoxy]phenyl]-  
1H-benzimidazole;

2-[4-[3-[4-(2,3-Dichlorophenyl)-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

2-[4-[3-[4-(2-Pyridinyl)-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

20 2-[4-[3-[4-(2-Pyrimidinyl)-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

2-[4-[3-[4-(4-Methylphenyl)-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

25 2-[4-[3-[4-(4-Fluorophenyl)-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

2-[4-[3-[4-[2-(Propylthio)phenyl]-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

2-[4-[3-(3,6-Dihydro-4-phenyl-1(2H)-  
pyridinyl)propoxy]phenyl]-1H-benzimidazole;

30 2-[4-[3-[4-(4-Chlorophenyl)-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

2-[4-[3-[4-(2-Methoxyphenyl)-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

35 2-[4-[3-[4-(4-Methoxyphenyl)-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

2-[4-[3-[4-(3-Chlorophenyl)-1-piperazinyl]-  
propoxy]phenyl]-1H-benzimidazole;

-8-

2-[4-[3-[4-(2,3-Dichlorophenyl)-1-piperazinyl]-  
propoxy]phenyl]-3H-imidazo[4,5-b]pyridine;  
1-Methyl-2-[4-[3-(4-phenyl-1-piperazinyl)-  
propoxy]phenyl]-1H-benzimidazole;  
5 2-[4-[4-(4-Phenyl-1-piperazinyl)-1-butynyl]-  
phenyl]-1H-benzimidazole;  
2-[4-[4-(4-Phenyl-1-piperazinyl)butoxy]phenyl]-1H-  
benzimidazole;  
N-[4-(1H-Benzimidazol-2-yl)phenyl]-4-phenyl-  
10 1-piperazine-3-propanamine;  
4-(1H-Benzimidazol-2-yl)-N-[2-(4-phenyl-  
1-piperazinyl)ethyl]benzamide;  
4-(1H-Benzimidazol-2-yl)-N-[2-[4-[2-(propylthio)-  
phenyl]-1-piperazinyl]ethyl]benzamide;  
15 4-(1H-Benzimidazol-2-yl)-N-[2-[4-  
(2-methoxyphenyl)-1-piperazinyl]ethyl]benzamide;  
(Z)-2-[4-[4-(4-Phenyl-1-piperazinyl)-  
1-butenyl]phenyl]-1H-benzimidazole; and  
2-[4-[4-(4-Phenyl-1-piperazinyl)butyl]phenyl]-1H-  
20 benzimidazole;  
or a pharmaceutically acceptable acid addition salt  
thereof.

The compounds of Formula I are valuable  
dopaminergic agents. Dopamine D2 antagonists are  
25 established as antipsychotic agents. More recently,  
the dopamine D3 receptor has been identified. On the  
basis of the localization of the dopamine D3 receptor  
in the limbic area of the brain, a selective D3  
antagonist should show antipsychotic activity but not  
30 have the neurological side effects of D2 antagonists.  
The tests employed indicate that compounds of Formula I  
bind selectively to the dopamine D3 receptor. Thus,  
the compounds of Formula I were tested for their  
ability to bind to dopamine receptors as measured by  
35 their inhibition of [<sup>3</sup>H]spiperone binding to the human  
D2 and D3 receptors in a receptor assay described by

-9-

MacKenzie R.G., et al., Characterization of the human D3 dopamine receptor expressed in transfected cell lines, Eur. J. Pharmacol., 266:79 (1994); and for their ability to inhibit locomotor activity in mice and rats, a measure of antipsychotic activity, according to the assay described by McLean J.R., et al., Pharmacology, Biochemistry and Behavior, 8:97-99 (1978). The above test methods are incorporated herein by reference. The data in Table 1 show the dopamine receptor binding activity of representative compounds of Formula I. The data in Table 2 show the locomotor activity of selected compounds of Formula I and demonstrate their utility as antipsychotic agents.

TABLE 1. Receptor Binding of Compounds of Formula I

Example Number	Compound	Inhibition of [ <sup>3</sup> H]Spiperone Binding to Human D3 Receptors IC <sub>50</sub> , nM	Inhibition of [ <sup>3</sup> H]Spiperone Binding to Human D2 Receptors IC <sub>50</sub> , nM
1	2-[4-[3-(4-Phenyl-1-piperazinyl)propoxy]-phenyl]-1H-benzimidazole	1.0	406
2	2-[4-[3-[2,3-Dichlorophenyl]-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole	1.7	45
3	2-[4-[3-[4-(2-Pyridinyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole	8	70
4	2-[4-[3-[4-(2-Pyrimidinyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole	15	269
5	2-[4-[3-[4-(4-Methylphenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole	102	2776
6	2-[4-[3-[4-(4-Fluorophenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole	16	119
7	2-[4-[3-[4-[2-(Propylthio)phenyl]-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole	1.3	3.7
8	2-[4-[3-(3,6-Dihydro-4-phenyl-1(2H)-pyridinyl)propoxy]phenyl]-1H-benzimidazole	18	672
9	2-[4-[3-[4-(4-Chlorophenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole	27	784

TABLE 1. Receptor Binding of Compounds of Formula I (cont.)

Example Number	Compound	Inhibition of [3H]Spiperone Binding to Human D3 Receptors		Inhibition of [3H]Spiperone Binding to Human D2 Receptors	
		IC <sub>50</sub> , nM		IC <sub>50</sub> , nM	
10	2-[4-[3-[4-(2-Methoxyphenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole	1.7		8	
11	2-[4-[3-[4-(4-Methoxyphenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole	130		265	
12	2-[4-[3-[4-(3-Chlorophenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole	155		1271	
13	2-[4-[3-[4-(2,3-Dichlorophenyl)-1-piperazinyl]-propoxy]phenyl]-3H-imidazo[4,5-b]pyridine	3		329	
14	1-Methyl-2-[4-[3-(4-phenyl-1-piperazinyl)-propoxy]phenyl]-1H-benzimidazole	9.5		219	
15	2-[4-[4-(4-Phenyl-1-piperazinyl)-1-butynyl]-phenyl]-1H-benzimidazole	1.7		581	
16	2-[4-[4-(4-Phenyl-1-piperazinyl)butoxy]phenyl]-1H-benzimidazole	1.7		46	
17	N-[4-(1H-Benzimidazol-2-yl)phenyl]-4-phenyl-1-piperazine-3-propanamine	1.6		22	
18	4-(1H-Benzimidazol-2-yl)-N-[2-(4-phenyl-1-piperazinyl)ethyl]benzamide	26		281	

TABLE 1. Receptor Binding of Compounds of Formula I (cont.)

Example Number	Compound	Inhibition of [ <sup>3</sup> H]Spiperone Binding to Human D3 Receptors		Inhibition of [ <sup>3</sup> H]Spiperone Binding to Human D2 Receptors	
		IC <sub>50</sub> , nM		IC <sub>50</sub> , nM	
19	4-(1H-Benzimidazol-2-yl)-N-[2-[4-[2-(propylthio)phenyl]-1-piperazinyl]-ethyl]benzamide	19		119	
20	4-(1H-Benzimidazol-2-yl)-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]benzamide	24		55	
21	(2)-2-[4-[4-(4-Phenyl-1-piperazinyl)-1-butenyl]phenyl]-1H-benzimidazole	81		100	
22	2-[4-[4-(4-Phenyl-1-piperazinyl)butyl]phenyl]-1H-benzimidazole	1.3		32	


-12-

-13-

TABLE 2. Locomotor Activity of Selected Compounds of Formula I

Example Number	Compound	Inhibition of Locomotor Activity in Rats ED <sub>50</sub> , mg/kg, IP
1	2-[4-[3-(4-Phenyl-1-piperazinyl)propoxy]-phenyl]-1H-benzimidazole	2.3
13	2-[4-[3-[4-(2,3-Dichlorophenyl)-1-piperazinyl]-propoxy]phenyl]-3H-imidazo[4,5-b]pyridine	4.2


10 A compound of Formula Ia




Ia

15

wherein R is



20

wherein R<sup>1</sup> is aryl, or heteroaryl, or

25

wherein R<sup>1</sup> is as defined above;R<sup>2</sup> is H or alkyl of from 1 to 6 carbon atoms;X<sup>a</sup> is -Y-(CH<sub>2</sub>)<sub>n</sub>-

30


wherein Y is O or S and n is an integer from 2 to 5;

-14-

Z is N or CH;

and corresponding isomers thereof; or a  
pharmaceutically acceptable acid addition salt thereof  
may be prepared by reacting a compound of Formula II

5




II

10

where  $R^2$  and Z are as defined above with a compound of  
Formula III

15



III

20.

wherein R and  $X^a$  is as defined above; in an  
oxidizing solvent such as, for example, nitrobenzene  
and the like at about 100°C to about 200°C from about  
1 hour to about 24 hours. Alternatively, the reaction  
may be carried out in the presence of an oxidant such  
as, for example, sodium bisulfite or copper (II)  
acetate and the like in a solvent such as, for example,  
methanol and the like at about room temperature to  
about the reflux temperature of the solvent at about  
2 hours to about 24 hours. Preferably, the reaction is  
carried out with sodium bisulfite in methanol at reflux  
temperature for about 6 hours.

25

30

A compound of Formula III may be prepared by  
reacting 4-hydroxybenzaldehyde or  
4-thiohydroxybenzaldehyde with a strong base such as,  
for example, sodium hydride, butyllithium and the like  
in a solvent such as, for example, tetrahydrofuran,



-15-

dimethylformamide and the like at about 0°C to about 80°C followed by treatment with a compound of Formula IV

5




IV

10

wherein Hal is halogen and n and R are as defined above for about 2 hours to about 24 hours. Preferably, the reaction is carried out in dimethylformamide with sodium hydride at about 60°C for about 6 hours.

A compound of Formula Ib


15



Ib


20

wherein R is



wherein R<sup>1</sup> is as defined above, or

25



wherein R<sup>1</sup> is as defined above;

R<sup>2</sup> is H or

30

alkyl of from 1 to 6 carbon atoms;

n is an integer from 2 to 5;

Z is N or CH;


and corresponding isomers thereof; or a

pharmaceutically acceptable acid addition salt thereof

35

may be prepared by reacting a compound of Formula Ic

-16-




5

wherein R, R<sup>2</sup>, Z and n are as defined above with an amide reducing agent such as, for example, lithium aluminum hydride, borane-dimethyl sulfide complex and the like in a solvent such as, for example, tetrahydrofuran and the like at about -20°C to about the reflux temperature of the solvent at about 1 hour to about 24 hours. Preferably, the reaction is carried out with borane-dimethylsulfide complex in tetrahydrofuran at the reflux temperature of the solvent for about 2 hours.

15

A compound of Formula Ic may be prepared by treatment of a compound of Formula V

20



25

wherein R<sup>2</sup> and Z are as defined above with a compound of Formula VI



30

wherein R and n are as defined above with a peptide coupling agent such as, for example, dicyclohexylcarbodiimide, isobutylchloroformate and the like in a solvent such as, for example, dichloromethane, dimethylformamide and the like with a base such as, for example, triethylamine and the like


35

-17-

at about -30°C to about 50°C for about 30 minutes to about 24 hours. Preferably, the reaction is carried out with isobutylchloroformate in dichloromethane at about -20°C for about 4 hours with triethylamine as base.


5 A compound of Formula V may be prepared by reacting a compound of Formula II with 4-acetamidobenzaldehyde in nitrobenzene as solvent at about 100°C to about 200°C for about 1 hour to about 10 24 hours. Alternatively, the reaction may be carried out in the presence sodium bisulfite or copper (II) acetate in a solvent such as, for example, methanol and the like at about room temperature to about the reflux temperature of the solvent for about 2 hours to about 15 24 hours. Preferably, the reaction is carried out with sodium bisulfite in methanol at reflux temperature for about 6 hours. The resulting acetamide may be converted to a compound of Formula V by treatment with a strong aqueous acid such as, for example aqueous 20 hydrochloric acid and the like at about room temperature to about reflux temperature for about 1 hour to about 6 hours. Preferably, the reaction is carried out with aqueous hydrochloric acid at about reflux temperature for about 1 hour.

25 A compound of Formula Id




-18-

wherein R is



5

wherein  $R^1$  is as defined above, or



wherein  $R^1$  is as defined above;

10

 $R^2$  is H or

alkyl of from 1 to 6 carbon atoms;


p is an integer from 1 to 4;

Z is N or CH;

and corresponding isomers thereof; or a

15

pharmaceutically acceptable acid addition salt thereof may be prepared by reacting a compound of Formula VII




VII

20

25

wherein R<sup>2</sup> and Z are as defined above with a compound of Formula VIII



VIII

30

wherein R and p are as defined above with a peptide coupling agent such as, for example, dicyclohexylcarbodiimide, isobutylchloroformate and the like in a solvent such as, for example, dichloromethane, dimethylformamide and the like with a base such as, for example, triethylamine and the like at about -30°C to about 50°C for about 30 minutes to about 24 hours. Preferably, the reaction is carried out with


35

-19-

isobutylchloroformate in dichloromethane at about  $-20^{\circ}\text{C}$  for about 4 hours with triethylamine as base.

A compound of Formula VII may be prepared by saponification of a compound of Formula IX

5



IX


10

wherein R<sup>3</sup> is alkyl of from 1 to 6 carbon atoms and R<sup>2</sup> and Z are as defined above by treatment with an alkali metal hydroxide in a solvent such as, for example, tetrahydrofuran and the like in the presence of water at about room temperature to about the reflux temperature of the solvent for about 1 hour to about 24 hours. Preferably, the reaction is carried out with sodium hydroxide in tetrahydrofuran at the reflux temperature of the solvent for about 2 hours.

15

A compound of Formula IX may be prepared by reaction of a compound of Formula II with a compound of Formula X

20



X

25

wherein R<sup>3</sup> is as defined above in nitrobenzene as solvent at about  $100^{\circ}\text{C}$  to about  $200^{\circ}\text{C}$  for about 1 hour to about 24 hours. Alternatively, the reaction may be carried out in the presence of sodium bisulfite or copper (II) acetate in a solvent such as, for example, methanol and the like at about room temperature to about the reflux temperature of the solvent for about 2 hours to about 24 hours. Preferably, the reaction is

30


35

-20-

carried out with sodium bisulfite in methanol at the reflux temperature of the solvent for about 6 hours.


A compound of Formula Ie

5




10

wherein R is



15

wherein R<sup>1</sup> is as defined above, or



20

wherein R<sup>1</sup> is as defined above;

R<sup>2</sup> is H or

alkyl of from 1 to 6 carbon atoms;


p is an integer from 1 to 4;

25

Z is N or CH;

and corresponding isomers thereof; or a pharmaceutically acceptable acid addition salt thereof may be prepared by reacting a compound of Formula II with a compound of Formula XI

30




35

wherein R and p are as defined above in an oxidizing solvent such as, for example, nitrobenzene and the like

-21-

at about 100°C to about 200°C for about 1 hour to about 24 hours. Alternatively, the reaction may be carried out in the presence of an oxidant such as, for example, sodium bisulfite, copper (II) acetate and the like in a solvent such as, for example, methanol and the like at about room temperature to about the reflux temperature of the solvent for about 2 hours to about 24 hours. Preferably, the reaction is carried out with sodium bisulfite in methanol at the reflux temperature of the solvent for about 6 hours.


A compound of Formula XI may be prepared by reacting 4-bromobenzaldehyde with a compound of Formula XII



wherein R and p are as defined above in a solvent such as, for example, acetonitrile, dimethylformamide and the like with a transition metal catalyst such as, for example, palladium (II) acetate or bis(triphenylphosphine)palladium (II) chloride. The reaction is carried out in the presence of a copper salt and a base such as, for example, triethylamine and the like at about room temperature to about the reflux temperature of the solvent for about 1 hour to about 24 hours. Preferably, the reaction is carried out in acetonitrile with bis(triphenylphosphine)palladium (II) chloride, copper (I) iodide, and triethylamine at room temperature for about 14 hours.

-22-


A compound of Formula If




If

5

wherein R is

wherein R<sup>1</sup> is as defined above, or

10

wherein R<sup>1</sup> is as defined above;

15

R<sup>2</sup> is H or

alkyl of from 1 to 6 carbon atoms;

X<sup>b</sup> is alkyl of from 3 to 6 carbon atoms or alkenyl  
of from 3 to 6 carbon atoms;

Z is N or CH;

20

and corresponding isomers thereof; or a  
pharmaceutically acceptable acid addition salt thereof  
may be prepared by hydrogenation of a compound of  
Formula Ie in a solvent such as, for example,  
tetrahydrofuran, ethanol and the like in the presence  
25 of a catalyst such as, for example, palladium on  
carbon, a poisoned catalyst and the like for about  
1 hour to about 24 hours. Preferably, for the  
preparation of the alkenes, palladium on calcium  
carbonate poisoned with lead is used in ethanol for  
30 about 1 hour. Preferably, for the preparation of



-23-

alkanes, palladium on carbon in ethanol for 6 hours is used.

5       Compounds II, IV, VI, VIII, X, and XII are either known or capable of being prepared by methods known in the art.

      The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection,  
10       that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of  
15       the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a  
20       compound of Formula I.

      For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets,  
25       pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating  
30       agents, or an encapsulating material.

      In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

      In tablets, the active component is mixed with the  
35       carrier having the necessary binding properties in

-24-

suitable proportions and compacted in the shape and size desired.

5       The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is  
10       intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly,  
15       cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

20       For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

25       Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

30       Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.

35       Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or

-25-

synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 1 mg to 1000 mg, preferably 10 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use as antipsychotic agents, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 1 mg to about 50 mg per kilogram daily. A daily dose range of about 5 mg to about 25 mg per kilogram is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the

-26-

compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention.

## EXAMPLE 1

2-[4-[3-(4-Phenyl-1-piperazinyl)propoxy]phenyl]-1H-benzimidazole

A mixture of 1,2-diaminobenzene (0.67 g) and 4-[3-(4-phenylpiperazin-1-yl)propoxy]benzaldehyde (Example A) (2.00 g) in nitrobenzene (65 mL) is stirred for 16 hours at 160°C. The solvent is distilled off under high vacuum and the resulting solid is purified by medium pressure liquid chromatography (MPLC) on silica gel eluting with 200:8:1 dichloromethane: ethanol:0.880 aqueous ammonia to give 0.97 g of the title compound as a tan solid; mp 240-244°C.

In a process analogous to Example 1 using appropriate starting materials, the corresponding compounds of Formula I are prepared as follows:

## EXAMPLE 2

2-[4-[3-[4-(2,3-Dichlorophenyl)-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole; mp 207-209°C.

-27-

## EXAMPLE 3

2-[4-[3-[4-(2-Pyridinyl)-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole; mp 218-220°C.

5

## EXAMPLE 4

2-[4-[3-[4-(2-Pyrimidinyl)-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole; mp 222-227°C.

## EXAMPLE 5

10 2-[4-[3-[4-(4-Methylphenyl)-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole; mp 222-225°C.

## EXAMPLE 6

15 2-[4-[3-[4-(4-Fluorophenyl)-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole; mp 221-224°C.

## EXAMPLE 7

20 2-[4-[3-[4-[2-(Propylthio)phenyl]-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole; mp 207-209°C.

## EXAMPLE 8

2-[4-[3-(3,6-Dihydro-4-phenyl-1(2H)-pyridinyl)propoxy]phenyl]-1H-benzimidazole; mp 227-232°C.

25

## EXAMPLE 9

2-[4-[3-[4-(4-Chlorophenyl)-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole; mp 241-243°C.

## EXAMPLE 10

30 2-[4-[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole; mp 228-230°C.

## EXAMPLE 11

35 2-[4-[3-[4-(4-Methoxyphenyl)-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole; mp 222-224°C.

-28-

## EXAMPLE 12

2-[4-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propoxy]-phenyl]-1H-benzimidazole; mp 221-223°C.

5

## EXAMPLE 13

2-[4-[3-[4-(2,3-Dichlorophenyl)-1-piperazinyl]-propoxy]phenyl]-3H-imidazo[4,5-b]pyridine;  
mp 229-230°C.

10

## EXAMPLE 14

1-Methyl-2-[4-[3-(4-phenyl-1-piperazinyl)propoxy]-phenyl]-1H-benzimidazole

Potassium hexamethyldisilazide (4 mL of 0.5 M in toluene) is added to 2-[4-[3-(4-phenyl-1-piperazinyl)-propoxy]phenyl]-1H-benzimidazole (Example 1) (0.75 g) in dimethylformamide (15 mL) at room temperature and stirred for 1 hour. Methyl iodide (0.14 mL) is added and the mixture stirred for 4 hours. Water (100 mL) is added and the mixture is extracted with dichloromethane (2 x 75 mL). The extracts are dried over MgSO<sub>4</sub>, filtered and evaporated to leave a solid. This solid is purified by MPLC on silica gel eluting with 200:8:1 dichloromethane:ethanol:0.880 aqueous ammonia to give 0.34 g of the title compound as a white solid; mp 151-154°C.

25

## EXAMPLE 15

2-[4-[4-(4-Phenyl-1-piperazinyl)-1-butyryl]phenyl]-1H-benzimidazole

30

A mixture of 4-[4-(4-phenylpiperazin-1-yl)but-1-ynyl]benzaldehyde (Example B) (1.28 g), sodium bisulfite (0.4 g) and 1,2-diaminobenzene (0.43 g) is stirred in methanol (50 mL) at reflux for 18 hours. The mixture is filtered and the solvent evaporated. The residue is purified by chromatography on silica gel eluting with 200:8:1 dichloromethane:ethanol:0.880

35

-29-

aqueous ammonia to give 0.70 g of the title compound as a tan solid; mp 247-248°C.

## EXAMPLE 16

5     2-[4-[4-(4-Phenyl-1-piperazinyl)butoxy]phenyl]-  
      1H-benzimidazole

      A mixture of 2-[4-(4-chlorobutoxy)phenyl]-  
      1H-benzimidazole (Example C) (0.25 g) and  
      1-phenylpiperazine (0.70 g) is stirred at 110°C in  
10     dimethylformamide (20 mL) for 6 hours. The solvent is  
      evaporated and the residue is purified by  
      chromatography on silica gel eluting with 100:8:1  
      dichloromethane:ethanol:0.880 aqueous ammonia to give  
      0.15 g of the title compound as a brown solid;  
15     mp 193-196°C.

## EXAMPLE 17

N-[4-(1H-Benzimidazol-2-yl)phenyl]-4-phenyl-  
      1-piperazine-3-propanamine

20     A mixture of [4-(1-benzyl-1H-benzimidazol-  
      2-yl)phenyl]-[3-(4-phenylpiperazin-1-yl)propyl]amine  
      (Example D) (0.29 g), 10% palladium on carbon (0.3 g)  
      and ammonium formate (0.18 g) is stirred in methanol  
      (10 mL) at reflux under nitrogen for 5 hours. The  
25     mixture is filtered through Celite and evaporated. The  
      residue is purified by MPLC on silica gel eluting with  
      200:8:1 dichloromethane:ethanol:0.880 aqueous ammonia  
      to give 0.14 g of the title compound as a yellow solid;  
      mp 231-234°C.

30

-30-

## EXAMPLE 18

4-(1H-Benzimidazol-2-yl)-N-[2-(4-phenyl-1-piperazinyl)-ethyl]benzamide

5 A mixture of 4-(1H-benzimidazol-2-yl)benzoic acid (Example E) (0.50 g), 2-(4-phenylpiperazin-1-yl)-ethylamine (0.77 g), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.44 g) and triethylamine (0.29 mL) in dichloromethane (20 mL) is stirred at room temperature for 2 days. The mixture is washed with water (50 mL), dried over MgSO<sub>4</sub>, filtered and evaporated. The residue is purified by MPLC on silica gel eluting with 100:8:1 dichloromethane: ethanol:0.880 aqueous ammonia to give 0.33 g of the title compound as a beige solid; mp 190-192°C.

15

In a process analogous to Example 18 using appropriate starting materials, the corresponding compounds of Formula I are prepared as follows:

20

## EXAMPLE 19

4-(1H-Benzimidazol-2-yl)-N-[2-[4-[2-(propylthio)-phenyl]-1-piperazinyl]ethyl]benzamide; mp 205-207°C.

## EXAMPLE 20

25

4-(1H-Benzimidazol-2-yl)-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]benzamide; mp 243-244°C.

## EXAMPLE 21

30

(Z)-2-[4-[4-(4-Phenyl-1-piperazinyl)-1-butenyl]phenyl]-1H-benzimidazole

35 A mixture of 2-(4-bromophenyl)-1H-benzimidazole (Example F) (8.08 g), 1-but-3-enyl-4-phenylpiperazine (Example G) (8.0 g), palladium acetate (0.66 g), tri-*o*-tolylphosphine (1.8 g) and triethylamine (7.05 g) in acetonitrile (100 mL) is stirred at reflux for 2 hours. The mixture is cooled and filtered through Celite. The



-31-

filtrate is evaporated to leave a brown solid. This solid is purified by MPLC on silica gel eluting with 100:8:1 dichloromethane:ethanol:0.880 aqueous ammonia to give 1.84 g of the title compound as a white solid; mp 140-145°C.

## EXAMPLE 22

2-[4-[4-(4-Phenyl-1-piperazinyl)butyl]phenyl]-1H-benzimidazole

(Z)-2-[4-[4-(4-Phenyl-1-piperazinyl)-1-butenyl]-phenyl]-1H-benzimidazole (Example 21) (0.5 g) is hydrogenated with 5% palladium on carbon (0.1 g) in methanol (10 mL) and filtered. The filtrate is evaporated and the residue is purified by MPLC on silica gel eluting with 100:8:1 dichloromethane:ethanol:0.880 aqueous ammonia to give 0.31 g of the title compound as a white solid; mp 239-243°C.

20

## PREPARATION OF STARTING MATERIALS

## EXAMPLE A

Preparation of 4-[3-[4-Phenylpiperazin-1-yl]propoxy]-benzaldehyde

25

Step A: Preparation of 1-(3-Chloropropyl)-4-phenylpiperazine

1-Phenylpiperazine (100 g) is added dropwise to 1-bromo-3-chloropropane (49 g) in diethyl ether (30 mL) and dichloromethane (100 mL). The mixture is stirred at 50°C for 4 hours. The mixture is filtered and the filtrate is extracted with 2N hydrochloric acid (3 x 300 mL). The extracts are basified with potassium carbonate and extracted with dichloromethane (3 x 300 mL). The extracts are dried over magnesium sulfate, filtered and evaporated to leave a brown oil.

-32-

This oil is distilled at 135-160°C/0.4 mm Hg to give 24.4 g of the title compound as a clear, colorless oil.

Step B: Preparation of 4-[3-(4-Phenylpiperazin-1-yl)-propoxy]benzaldehyde

5 Sodium hydride (3.59 g of 60% in oil) is added to 4-hydroxybenzaldehyde (9.95 g) in dimethylformamide (250 mL) and the mixture stirred at 60°C for 30 minutes. 1-(3-Chloropropyl)-4-phenylpiperazine  
10 (Step A) (19.5 g) is added and the mixture stirred for 14 hours at 60°C. The solvent is evaporated and the residue treated with water (300 mL) and extracted with dichloromethane (3 × 150 mL). The extracts are dried over magnesium sulfate, filtered and evaporated to  
15 leave a beige solid. This solid is recrystallized from ethyl acetate/diethyl ether to give 18.4 g of the title compound as a light beige solid.

EXAMPLE B

20 Preparation of 4-[4-(4-Phenylpiperazin-1-yl)but-1-ynyl]benzaldehyde

Step A: Preparation of 1-But-3-ynyl-4-phenylpiperazine

A mixture of but-3-ynyl-p-toluenesulfonate  
25 (8.97 g), 1-phenylpiperazine (6.49 g) and sodium bicarbonate (3.7 g) in dimethylformamide (100 mL) is stirred at 80°C for 14 hours. The solvent is evaporated and the residue dissolved in dichloromethane, washed with water and dried over  
30 MgSO<sub>4</sub>. The solution is filtered through silica gel and the product eluted with 10% ethyl acetate/hexanes to give 6.76 g of the title compound as a white solid.

-33-

Step B: Preparation of 4-[4-(4-Phenylpiperazin-1-yl)but-1-ynyl]benzaldehyde

A mixture of 4-bromobenzaldehyde (4.05 g), 1-but-3-ynyl-4-phenylpiperazine (Step A) (4.69 g),  
5 triethylamine (9.2 mL), bis(triphenylphosphine)-palladium dichloride (0.31 g) and copper (I) iodide (0.08 g) in acetonitrile (100 mL) is degassed with nitrogen and stirred at room temperature for 16 hours. The solvent is evaporated and the residue is dissolved  
10 in dichloromethane (200 mL), washed with 2N sodium carbonate (150 mL), dried over  $\text{MgSO}_4$ , filtered and evaporated to leave a brown oil. This oil is purified by MPLC on silica gel eluting with 15% then 30% ethyl acetate (EtOAc)/hexanes to give 4.2 g of the title  
15 compound as a yellow waxy solid.

EXAMPLE C

Preparation of 2-[4-(4-Chlorobutoxy)phenyl]-1H-benzimidazole

20

Step A: Preparation of 4-(4-Chlorobutoxy)benzaldehyde

4-Hydroxybenzaldehyde (26.4 g) in dimethylformamide (50 mL) is added to sodium hydride (8.64 g of 60% in oil) in dimethylformamide (200 mL). 1-Bromo-  
25 3-chloropropane (93.2 g) is added and the mixture stirred at 60°C for 3 hours. The mixture is poured into water (400 mL) and extracted with diethyl ether (3 x 150 mL). The extracts are dried over  $\text{MgSO}_4$ , filtered and evaporated to leave an orange oil. The  
30 oil is distilled and 40.7 g of the title compound collected at 158-175°C/0.7 mmHg as a yellow oil.

Step B: Preparation of 2-[4-(4-Chlorobutoxy)phenyl]-1H-benzimidazole

35

A mixture of copper (II) acetate monohydrate (7.76 g), 1,2-diaminobenzene (2.10 g),

-34-

4-(4-chlorobutoxy)benzaldehyde (Step A) (5.0 g) is slowly heated to reflux in water (10 mL) and methanol (100 mL) and stirred at reflux for 1 hour. The mixture is cooled and a brown precipitate filtered off. The precipitate is suspended in methanol (100 mL) and hydrogen sulfide bubbled through for 30 minutes followed by nitrogen. The mixture is heated to reflux, cooled and filtered. All the filtrates are combined and 0.880 ammonium hydroxide added until just basic. The filtrates are diluted with an equal volume of water and the resulting pale-grey precipitate collected. The precipitate is recrystallized from methanol/water to give 3.8 g of the title compound.

15

## EXAMPLE D

Preparation of [4-(1-Benzyl-1H-benzimidazol-2-yl)-phenyl]-[3-(4-phenylpiperazin-1-yl)propyl]amine

20

Step A: Preparation of 4-(1-Benzyl-1H-benzimidazol-2-yl)phenylamine

25

30

35

Benzyl-(2-nitrophenyl)amine (20 g) is hydrogenated with Raney nickel in methanol (600 mL) and filtered. The filtrate is added to 4-acetamidobenzaldehyde (14.3 g) and sodium bisulfite (9.3 g) in methanol (200 mL) and the mixture stirred at reflux for 8 hours. The mixture is filtered and evaporated to leave a brown foam. This foam is stirred at reflux in concentrated hydrochloric acid (200 mL) and water (300 mL) for 3 hours. The cooled mixture is basified with 25% sodium hydroxide. The mixture is extracted with dichloromethane (2 x 200 mL), the extracts dried over MgSO<sub>4</sub>, filtered and evaporated to leave a brown oil. The oil is diluted with ethyl acetate to precipitate a brown solid which is recrystallized from ethyl acetate/diethyl ether to give 8.3 g of the title compound as a brown solid.

-35-

Step B: Preparation of N-[4-(1-Benzyl-1H-benzimidazol-2-yl)phenyl]-3-(4-phenylpiperazin-1-yl)propionamide

i-Butylchloroformate (0.24 mL) is added to 4-phenylpiperazin-1-ylpropanoic acid (0.39 g) and triethylamine (0.28 mL) in dichloromethane (10 mL) at -20°C under nitrogen. After stirring for 30 minutes, 4-(1-benzyl-1H-benzimidazol-2-yl)phenylamine (Step A) (0.50 g) in dichloromethane (10 mL) is added dropwise at -20°C and the mixture allowed to warm to room temperature with stirring. The mixture is diluted with dichloromethane (50 mL), washed with 2N sodium carbonate (50 mL), dried over MgSO<sub>4</sub>, filtered and evaporated to leave a yellow oil. This oil is purified by MPLC on silica gel eluting with 250:8:1 dichloromethane:ethanol:0.880 aqueous ammonia to give 0.66 g of the title compound as a yellow foam.

Step C: Preparation of [4-(1-Benzyl-1H-benzimidazol-2-yl)phenyl]-[3-(4-phenylpiperazin-1-yl)propyl]amine

Borane.THF (3.5 mL of 1.0 M in tetrahydrofuran (THF)) is added to N-[4-(1-benzyl-1H-benzimidazol-2-yl)phenyl]-3-(4-phenylpiperazin-1-yl)propionamide (Step B) (0.45 g) in THF (10 mL) and the mixture stirred at reflux for 2 hours. 2N Hydrochloric acid (5 mL) is added and the mixture stirred for 30 minutes. The solvent is evaporated and the residue treated with 2N sodium carbonate (100 mL). The mixture is extracted with dichloromethane (3 x 50 mL) and the extracts are dried over MgSO<sub>4</sub>, filtered and evaporated to leave a yellow oil. This oil is purified by MPLC on silica gel eluting with 300:8:1 dichloromethane:ethanol:0.880 aqueous ammonia to give 0.31 g of the title compound as a white solid.

-36-

## EXAMPLE E

Preparation of 4-(1H-Benzimidazol-2-yl)benzoic acidStep A: Preparation of Methyl 4-(1H-benzimidazol-2-yl)benzoate

A mixture of 1,2-diaminobenzene (6.59 g), methyl 4-formylbenzoate (10.0 g) and sodium bisulfite (6.60 g) in methanol (500 mL) is stirred at reflux for 6 hours. The mixture is filtered and the solvent evaporated to leave a yellow solid. This solid is recrystallized from ethyl acetate/ethanol to give 2.92 g of the title compound as an off-white solid.

Step B: Preparation of 4-(1H-Benzimidazol-2-yl)benzoic acid

Methyl 4-(1H-benzimidazol-2-yl)benzoate (Step A) (2.63 g) is stirred in THF (50 mL) and water (10 mL) with sodium hydroxide (2.08 g) at reflux for 4 hours. The solvent is evaporated and the residue treated with 2N hydrochloric acid (100 mL). The resulting suspension is collected, washed with methanol/ethyl acetate and dried to give 2.52 g of the title compound as a white solid.

## EXAMPLE F

Preparation of 2-(4-Bromophenyl)-1H-benzimidazole

Sodium bisulfite (14.4 g) is added to 4-bromobenzaldehyde (17.1 g) in ethanol (100 mL) and the mixture stirred at reflux for 15 minutes. 1,2-Diaminobenzene (10 g) is added and the mixture stirred at reflux for 16 hours. The solvent is evaporated and the residue is washed with water and ethanol to afford 18.0 g of the title compound as a beige solid.

-37-

## EXAMPLE G


Preparation of 1-But-3-enyl-4-phenylpiperazine

5 A mixture of 4-bromobut-1-ene (8.68 g) and  
1-phenylpiperazine (35.7 g) is heated to reflux in  
diethyl ether (100 mL) for 2 hours. The mixture is  
filtered and the filtrate is extracted with 2N  
hydrochloric acid (150 mL). The extracts are washed  
with diethyl ether (150 mL) and basified with 25%  
sodium hydroxide. The aqueous layer is extracted with  
10 diethyl ether (3 × 100 mL), the extracts dried over  
MgSO<sub>4</sub>, filtered and evaporated to leave a brown oil.  
This oil is purified by MPLC on silica gel eluting with  
5% methanol in dichloromethane to give 10.4 g of the  
title compound as a yellow oil.


-38-

## CLAIMS


1. A compound of Formula I



10  
wherein R is




15  
wherein R<sup>1</sup> is aryl, or heteroaryl,  
or




wherein R<sup>1</sup> is as defined above;  
R<sup>2</sup> is hydrogen, or alkyl of from 1 to  
6 carbon atoms;

25  
X is -Y-(CH<sub>2</sub>)<sub>n</sub>-  
wherein Y is O, S or NH, and n is an  
integer from 2 to 5,



wherein p is an integer from 1 to 4,



wherein p is as defined above,  
alkyl of from 3 to 6 carbon atoms,  
alkenyl of from 3 to 6 carbon atoms,




-39-

alkynyl of from 3 to 6 carbon atoms;


Z is N or CH;

and corresponding isomers thereof; or a  
pharmaceutically acceptable acid addition salt  
thereof.

2. A compound according to Claim 1,





wherein R<sup>1</sup> is aryl, or heteroaryl, or



R<sup>2</sup> is hydrogen,  
methyl, or  
ethyl;

X is -Y-(CH<sub>2</sub>)<sub>n</sub>-

wherein Y is O or NH and n is an integer  
from 3 to 4,



butyl,  
butenyl, or  
butynyl;

Z is N or CH.

3. A compound according to Claim 2 selected from the  
group consisting of:

-40-

- 2-[4-[3-(4-Phenyl-1-piperazinyl)propoxy]-phenyl]-1H-benzimidazole;
- 5 2-[4-[3-[4-(2,3-Dichlorophenyl)-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole;
- 2-[4-[3-[4-(2-Pyridinyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole;
- 10 2-[4-[3-[4-(2-Pyrimidinyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole;
- 2-[4-[3-[4-(4-Methylphenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole;
- 2-[4-[3-[4-(4-Fluorophenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole;
- 15 2-[4-[3-[4-[2-(Propylthio)phenyl]-1-piperazinyl]propoxy]phenyl]-1H-benzimidazole;
- 2-[4-[3-(3,6-Dihydro-4-phenyl-1(2H)-pyridinyl)propoxy]phenyl]-1H-benzimidazole;
- 2-[4-[3-[4-(4-Chlorophenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole;
- 20 2-[4-[3-[4-(2-Methoxyphenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole;
- 2-[4-[3-[4-(4-Methoxyphenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole;
- 25 2-[4-[3-[4-(3-Chlorophenyl)-1-piperazinyl]-propoxy]phenyl]-1H-benzimidazole;
- 2-[4-[3-[4-(2,3-Dichlorophenyl)-1-piperazinyl]propoxy]phenyl]-3H-imidazo-[4,5-b]pyridine;
- 30 1-Methyl-2-[4-[3-(4-phenyl-1-piperazinyl)-propoxy]phenyl]-1H-benzimidazole;
- 2-[4-[4-(4-Phenyl-1-piperazinyl)-1-butynyl]-phenyl]-1H-benzimidazole;
- 2-[4-[4-(4-Phenyl-1-piperazinyl)butoxy]-phenyl]-1H-benzimidazole;
- 35 N-[4-(1H-Benzimidazol-2-yl)phenyl]-4-phenyl-1-piperazine-3-propanamine;

-41-

4-(1H-Benzimidazol-2-yl)-N-[2-(4-phenyl-  
1-piperazinyl)ethyl]benzamide;

40

4-(1H-Benzimidazol-2-yl)-N-[2-[4-  
[2-(propylthio)phenyl]-1-piperazinyl]ethyl]-  
benzamide;

45

4-(1H-Benzimidazol-2-yl)-N-[2-[4-  
(2-methoxyphenyl)-1-piperazinyl]ethyl]benzamide;


(Z)-2-[4-[4-(4-Phenyl-1-piperazinyl)-  
1-butenyl]phenyl]-1H-benzimidazole; and

2-[4-[4-(4-Phenyl-1-piperazinyl)butyl]-  
phenyl]-1H-benzimidazole.

4. A method of treating psychoses, psychotic  
depression, substance abuse and compulsive  
disorders comprising administering to a host  
suffering therefrom a therapeutic effective amount  
of a compound according to Claim 1 in unit dosage  
form.
5. A method of treating schizophrenia comprising  
administering to a host suffering therefrom a  
therapeutic effective amount of a compound  
according to Claim 1 in unit dosage form.
6. A pharmaceutical composition adapted for  
administration as an agent for treating  
schizophrenia comprising a therapeutic effective  
amount of a compound according to Claim 1 in  
admixture with a pharmaceutically acceptable  
excipient, diluent, or carrier.
7. A method of preparing a compound having the  
Formula Ia

-42-


5



Ia


10

wherein R is



wherein R<sup>1</sup> is aryl, or heteroaryl,  
or

15



wherein R<sup>1</sup> is as defined above;

20

R<sup>2</sup> is H or

alkyl of from 1 to 6 carbon atoms;

X<sup>a</sup> is -Y-(CH<sub>2</sub>)<sub>n</sub>-


wherein Y is O or S and n is an integer  
from 2 to 5;

25

Z is N or CH;

and corresponding isomers thereof; or a  
pharmaceutically acceptable acid addition salt  
thereof comprises reaction of a compound of  
Formula II

30



II

35

wherein R<sup>2</sup> and Z are as defined above with a  
compound of Formula III

-43-



III


40

45

50


wherein R and X<sup>a</sup> is as defined above;  
 in a solvent with an oxidant to afford a compound  
 of Formula Ia and, if desired, converting a  
 compound of Formula Ia to a corresponding  
 pharmaceutically acceptable acid addition salt by  
 conventional means and, if so desired, converting  
 the corresponding pharmaceutically acceptable acid  
 addition salt to a compound of Formula Ia by  
 conventional means.

8. A method of preparing a compound of Formula Ib




Ib

wherein R is



wherein R<sup>1</sup> is aryl, or heteroaryl,  
 or




-44-

wherein  $R^1$  is as defined above; $R^2$  is H or

alkyl of from 1 to 6 carbon atoms;


 $n$  is an integer from 2 to 5; $Z$  is N or CH;

and corresponding isomers thereof; or a  
 pharmaceutically acceptable acid addition salt  
 thereof comprises reduction of a compound of  
 Formula Ic



wherein  $R$ ,  $R^2$ ,  $Z$ , and  $n$  are as defined above with  
 an amide reducing agent in a solvent to afford a  
 compound of Formula Ib and, if desired, converting  
 a compound of Formula Ib to a corresponding  
 pharmaceutically acceptable acid addition salt by  
 conventional means and, if so desired, converting  
 the corresponding pharmaceutically acceptable acid  
 addition salt to a compound of Formula Ib by  
 conventional means.

9. A method of preparing a compound of Formula Id




5


10

-45-

wherein R is



wherein R¹ is aryl or heteroaryl,  
or



wherein R¹ is as defined above;


R² is H or

alkyl of from 1 to 6 carbon atoms;

p is an integer from 1 to 4;


Z is N or CH;

and corresponding isomers thereof; or a  
pharmaceutically acceptable acid addition salt  
thereof comprises coupling of a compound of  
Formula VII



VII

wherein R² and Z are as defined above with a  
compound of Formula VIII




VIII

wherein R and p are as defined above with a  
peptide coupling agent in a solvent to afford a  
compound of Formula Id and, if desired, converting  
a compound of Formula Id to a corresponding  
pharmaceutically acceptable acid addition salt by


-46-

conventional means and, if so desired, converting the corresponding pharmaceutically acceptable acid addition salt to a compound of Formula Id by conventional means.


10. A compound of Formula Ie



10 wherein R is



wherein R<sup>1</sup> is aryl or heteroaryl,  
or



wherein R<sup>1</sup> is as defined above;

20 R<sup>2</sup> is H or

alkyl of from 1 to 6 carbon atoms;

p is an integer from 1 to 4;


Z is N or CH;

and corresponding isomers thereof; or a  
25 pharmaceutically acceptable acid addition salt  
thereof comprises reaction of a compound of  
Formula II

30



-47-




II

35

wherein  $R^2$  and  $Z$  are as defined  
above with a compound of  
Formula XI;

40




XI

45

wherein  $R$  and  $p$  are as defined above with an  
oxidant in a solvent to afford a compound of  
Formula Ie and, if desired, converting a compound  
of Formula Ie to a corresponding pharmaceutically  
acceptable acid addition salt by conventional  
means and, if so desired, converting the  
corresponding pharmaceutically acceptable acid  
addition salt to a compound of Formula Ie by  
conventional means.

50

11. A compound of Formula If




If

-48-

5


wherein R is



10

wherein  $R^1$  is aryl or heteroaryl,  
or

15



wherein  $R^1$  is as defined above;

$R^2$  is H or

alkyl of from 1 to 6 carbon atoms;

20

$X^b$  is alkyl of from 3 to 6 carbon atoms or  
alkenyl of from 3 to 6 carbon atoms;

Z is N or CH;


and corresponding isomers thereof; or a

pharmaceutically acceptable acid addition salt

25

thereof comprises hydrogenation of a compound of  
Formula Ie

30



Ie

35

wherein p is an integer from 1 to 4 and R,  $R^2$  and  
Z are as defined above in a solvent to afford a  
compound of Formula If and, if desired, converting  
a compound of Formula If to a corresponding  
pharmaceutically acceptable acid addition salt by  
conventional means and, if so desired, converting  
40 the corresponding pharmaceutically acceptable acid

-49-

addition salt to a compound of Formula I by  
conventional means.

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/US 95/03816

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D235/18 C07D471/04 C07D403/12 C07D401/12 A61K31/415  
A61K31/435 A61K31/505 //(C07D471/04,235:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP-A-0 056 866 (BASF AKTIENGESELLSCHAFT) 4 August 1982 see the whole document ---	1-3,6-11
Y	US-A-4 891 375 (LOWE, III J.A.) 2 January 1990 see the whole document ---	1-3,6-11
Y	EP-A-0 372 776 (PFIZER INC.) 13 June 1990 see the whole document ---	1-3,6-11
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* " " document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

\* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* "&" document member of the same patent family

Date of the actual completion of the international search

26 July 1995

Date of mailing of the international search report

31. 08. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Hartrampf, G

## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 95/03816

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 72, no. 15, 13 April 1970 Columbus, Ohio, US; abstract no. 79042h, 'Benzimidazoles' page 405; column 2; see abstract & FR-A-1 570 892 (MANUFACTURES J. R. BOTTU) 13 June 1969 ---	1-3,6-11
A	CHEMICAL ABSTRACTS, vol. 72, no. 17, 27 April 1970 Columbus, Ohio, US; abstract no. 90473v, ROHRBACH P. & BLUM J. 'Antiinflammatory substituted 1,2-diphenylbenzimidazoles' page 402; column 1; see abstract & GB-A-1 174 493 (MANUFACTURES J. R. BOTTU) 17 December 1969 ---	1-3,6-11
A	CHEMICAL ABSTRACTS, vol. 75, no. 11, 13 September 1971 Columbus, Ohio, US; abstract no. 76797j, HASEGAWA G. & MARUYAMA H. 'Benzimidazole compounds' page 467; column 2; see abstract & JP-A-46 009 581 (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.) 11 March 1971 ---	1-3,6-11
A	US-A-4 003 908 (DENZEL T. & HOEHN H.) 18 January 1977 see the whole document ---	1-3,6-11
A	CHEMICAL ABSTRACTS, vol. 107, no. 5, 3 August 1987 Columbus, Ohio, US; abstract no. 39751y, NAGARAJAN K. ET AL. 'Quest for anthelmintic agents. Part I. Para substituted phenylisothiocyanates, heterocyclisothiocyanates and bisisothiocyanates' page 696; column 1; see abstract & INDIAN J. PHARM. SCI., vol. 48, no. 3, 1986 (HINDUSTAN CIBA-GEIGY LTD.), pages 54-59, -----	1-3,6-11

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 95/03816

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-56866	04-08-82	DE-A- 3101502 CA-A- 1187878 JP-A- 57146762 US-A- 4619929	26-08-82 28-05-85 10-09-82 28-10-86
US-A-4891375	02-01-90	NONE	
EP-A-372776	13-06-90	WO-A- 9006303 CA-A- 2004249 IL-A- 92466 JP-A- 2275853 JP-B- 7010850 NO-B- 175257 US-A- 5153206 US-A- 5294619	14-06-90 02-06-90 27-02-94 09-11-90 08-02-95 13-06-94 06-10-92 15-03-94
US-A-4003908	18-01-77	US-A- 4048182	13-09-77

# INTERNATIONAL SEARCH REPORT

1. International application No.

PCT/US 95/ 03816

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 4 and 5 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

